Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Asian Pac J Trop Biomed ; 1(6): 496-501, 2011 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-23569822

RESUMO

Anthrax is a zoonotic disease caused by Bacillus anthracis. It is potentially fatal and highly contagious disease. Herbivores are the natural host. Human acquire the disease incidentally by contact with infected animal or animal products. In the 18th century an epidemic destroyed approximately half of the sheep in Europe. In 1900 human inhalational anthrax occured sporadically in the United States. In 1979 an outbreak of human anthrax occured in Sverdlovsk of Soviet Union. Anthrax continued to represent a world wide presence. The incidence of the disease has decreased in developed countries as a result of vaccination and improved industrial hygiene. Human anthrax clinically presents in three forms, i.e. cutaneous, gastrointestinal and inhalational. About 95% of human anthrax is cutaneous and 5% is inhalational. Gastrointestinal anthrax is very rare (less than 1%). Inhalational form is used as a biological warefare agent. Penicillin, ciprofloxacin (and other quinolones), doxicyclin, ampicillin, imipenem, clindamycin, clarithromycin, vancomycin, chloramphenicol, rifampicin are effective antimicrobials. Antimicrobial therapy for 60 days is recommended. Human anthrax vaccine is available. Administration of anti-protective antigen (PA) antibody in combination with ciprofloxacin produced 90%-100% survival. The combination of CPG-adjuvanted anthrax vaccine adsorbed (AVA) plus dalbavancin significantly improved survival.


Assuntos
Antraz/epidemiologia , Antraz/veterinária , Bacillus anthracis/fisiologia , Zoonoses/epidemiologia , Zoonoses/patologia , Animais , Antraz/tratamento farmacológico , Antraz/patologia , Antibacterianos/farmacologia , Antibacterianos/uso terapêutico , Bacillus anthracis/efeitos dos fármacos , Armas Biológicas , Saúde Global , Humanos , Incidência , Zoonoses/microbiologia
2.
Eye (Lond) ; 22(8): 1054-6, 2008 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-17435682

RESUMO

AIMS: Recent data have raised concerns about visual outcome following cataract surgery. The aim of this study was to assess the frequency and causes of poor and borderline outcome after cataract surgery in a population-based case series in Satkhira district, Bangladesh. METHODS: A population-based case series was conducted within a population-based cluster survey of people aged over 50 years in Satkhira district where 4868 people underwent visual acuity (VA) screening. Eyes operated for cataract with VA<6/18 were examined in detail by an ophthalmologist, including a full history and dilated fundoscopy, to determine the cause of the visual outcome. RESULTS: Cataract surgery was performed on 213 eyes. Outcome was good (VA>6/18) for 128 eyes (60.1%), borderline (VA<6/18 to 6/60) for 35 eyes (16.4%), and poor (VA<6/60) for 50 eyes (23.5%) with available correction. Borderline and poor outcomes were most commonly due to lack of spectacles (25.8%), poor selection (33.8%), or surgical complications (30.6%). Surgical sequelae, namely posterior capsule opacification, was a less common cause of poor or borderline outcome (9.7%). CONCLUSIONS: Quality of surgical outcomes is of concern in Satkhira district. Increased emphasis on selection of subjects for surgery, provision of spectacles, and monitoring of surgery may improve outcomes.


Assuntos
Extração de Catarata , Países em Desenvolvimento , Idoso , Bangladesh , Extração de Catarata/efeitos adversos , Óculos/estatística & dados numéricos , Humanos , Pessoa de Meia-Idade , Seleção de Pacientes , Prognóstico , Fatores de Risco , Resultado do Tratamento , Transtornos da Visão/etiologia , Acuidade Visual
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...